1. Home
  2. PCRX vs AAT Comparison

PCRX vs AAT Comparison

Compare PCRX & AAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • AAT
  • Stock Information
  • Founded
  • PCRX 2006
  • AAT 1967
  • Country
  • PCRX United States
  • AAT United States
  • Employees
  • PCRX N/A
  • AAT N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • AAT Real Estate Investment Trusts
  • Sector
  • PCRX Health Care
  • AAT Real Estate
  • Exchange
  • PCRX Nasdaq
  • AAT Nasdaq
  • Market Cap
  • PCRX 1.2B
  • AAT 1.2B
  • IPO Year
  • PCRX 2011
  • AAT 2011
  • Fundamental
  • Price
  • PCRX $25.12
  • AAT $19.25
  • Analyst Decision
  • PCRX Buy
  • AAT Hold
  • Analyst Count
  • PCRX 9
  • AAT 2
  • Target Price
  • PCRX $29.89
  • AAT $21.00
  • AVG Volume (30 Days)
  • PCRX 782.0K
  • AAT 434.4K
  • Earning Date
  • PCRX 05-08-2025
  • AAT 04-29-2025
  • Dividend Yield
  • PCRX N/A
  • AAT 7.07%
  • EPS Growth
  • PCRX N/A
  • AAT 49.17
  • EPS
  • PCRX N/A
  • AAT 1.33
  • Revenue
  • PCRX $702,772,000.00
  • AAT $451,281,000.00
  • Revenue This Year
  • PCRX $9.48
  • AAT $4.44
  • Revenue Next Year
  • PCRX $11.31
  • AAT $1.87
  • P/E Ratio
  • PCRX N/A
  • AAT $14.52
  • Revenue Growth
  • PCRX 3.08
  • AAT 2.65
  • 52 Week Low
  • PCRX $11.16
  • AAT $16.69
  • 52 Week High
  • PCRX $31.67
  • AAT $29.15
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 48.10
  • AAT 51.26
  • Support Level
  • PCRX $25.08
  • AAT $18.91
  • Resistance Level
  • PCRX $27.34
  • AAT $19.38
  • Average True Range (ATR)
  • PCRX 1.16
  • AAT 0.45
  • MACD
  • PCRX -0.18
  • AAT 0.14
  • Stochastic Oscillator
  • PCRX 48.85
  • AAT 84.43

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About AAT American Assets Trust Inc.

American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.

Share on Social Networks: